Hypoadiponectinemia in overweight children contributes to a negative metabolic risk profile 6 years later

Iben Kynde; Berit L Heitmann; Ib C Bygbjerg; Lars B Andersen; Jørn W Helge

doi:10.1016/j.metabol.2009.06.014

Hypoadiponectinemia in overweight children contributes to a negative metabolic risk profile 6 years later

Iben Kynde, Berit L Heitmann, Ib C Bygbjerg, Lars B Andersen, Jørn W Helge

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

22 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009-Dec

Originalsprog	Engelsk
Tidsskrift	Metabolism - Clinical and Experimental
Vol/bind	58
Udgave nummer	12
Sider (fra-til)	1817-24
Antal sider	7
ISSN	0026-0495
DOI	https://doi.org/10.1016/j.metabol.2009.06.014
Status	Udgivet - 2009

Bibliografisk note

Keywords: Adiponectin; Adolescent; Blood Pressure; Body Mass Index; Child; Cytokines; Denmark; Disease Progression; Female; Hepatocyte Growth Factor; Humans; Insulin Resistance; Interleukin-8; Leptin; Lipids; Male; Metabolic Diseases; Overweight; Regression Analysis; Risk Assessment

Adgang til dokumentet

10.1016/j.metabol.2009.06.014

Citationsformater

@article{56e64a10334f11df8ed1000ea68e967b,

title = "Hypoadiponectinemia in overweight children contributes to a negative metabolic risk profile 6 years later",

abstract = "Prognostic biomarkers are needed to identify children at increased cardiometabolic risk. The objective was to study whether markers of metabolism and inflammation, for example, circulating plasma adiponectin, leptin, interleukin-8, and hepatocyte growth factor, are associated with cardiometabolic risk factors in childhood and adolescence. This was a cross-sectional and prospective study, and the setting was the Danish part of the European Youth Heart Studies I and II. Participants were randomly selected girls and boys 8 to 10 years of age with complete baseline data (n = 256) and complete follow-up data 6 years later (n = 169). Cardiometabolic risk profile was calculated using a continuous composite score derived from summing of 6 factors standardized to the sample means (Z scores): body mass index, homeostasis model assessment of insulin resistance, total serum cholesterol to serum high-density lipoprotein cholesterol ratio, serum triglycerides, systolic blood pressure, and the reciprocal value of fitness (maximum watts per kilogram). Overweight was defined using international classification of body mass index cutoff points for children. Plasma adiponectin, leptin, interleukin-8, and hepatocyte growth factor were assessed using immunochemical assays. Linear relationships were found between metabolic risk score and both plasma adiponectin (inverse, P = .02) and plasma leptin (P < .0001) at baseline after adjustment for several confounders. In overweight but not normal-weight children, plasma adiponectin at baseline was inversely associated with metabolic risk score 6 years later (P = .04). In childhood, both hypoadiponectinemia and hyperleptinemia accompany a negative metabolic risk profile. In addition, circulating plasma adiponectin may be a useful biomarker to identify overweight children at greater future risk of the cardiometabolic adverse effects of overweight.",

author = "Iben Kynde and Heitmann, {Berit L} and Bygbjerg, {Ib C} and Andersen, {Lars B} and Helge, {J{\o}rn W}",

note = "Keywords: Adiponectin; Adolescent; Blood Pressure; Body Mass Index; Child; Cytokines; Denmark; Disease Progression; Female; Hepatocyte Growth Factor; Humans; Insulin Resistance; Interleukin-8; Leptin; Lipids; Male; Metabolic Diseases; Overweight; Regression Analysis; Risk Assessment",

year = "2009",

doi = "10.1016/j.metabol.2009.06.014",

language = "English",

volume = "58",

pages = "1817--24",

journal = "Metabolism",

issn = "0026-0495",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - Hypoadiponectinemia in overweight children contributes to a negative metabolic risk profile 6 years later

AU - Kynde, Iben

AU - Heitmann, Berit L

AU - Bygbjerg, Ib C

AU - Andersen, Lars B

AU - Helge, Jørn W

N1 - Keywords: Adiponectin; Adolescent; Blood Pressure; Body Mass Index; Child; Cytokines; Denmark; Disease Progression; Female; Hepatocyte Growth Factor; Humans; Insulin Resistance; Interleukin-8; Leptin; Lipids; Male; Metabolic Diseases; Overweight; Regression Analysis; Risk Assessment

PY - 2009

Y1 - 2009

N2 - Prognostic biomarkers are needed to identify children at increased cardiometabolic risk. The objective was to study whether markers of metabolism and inflammation, for example, circulating plasma adiponectin, leptin, interleukin-8, and hepatocyte growth factor, are associated with cardiometabolic risk factors in childhood and adolescence. This was a cross-sectional and prospective study, and the setting was the Danish part of the European Youth Heart Studies I and II. Participants were randomly selected girls and boys 8 to 10 years of age with complete baseline data (n = 256) and complete follow-up data 6 years later (n = 169). Cardiometabolic risk profile was calculated using a continuous composite score derived from summing of 6 factors standardized to the sample means (Z scores): body mass index, homeostasis model assessment of insulin resistance, total serum cholesterol to serum high-density lipoprotein cholesterol ratio, serum triglycerides, systolic blood pressure, and the reciprocal value of fitness (maximum watts per kilogram). Overweight was defined using international classification of body mass index cutoff points for children. Plasma adiponectin, leptin, interleukin-8, and hepatocyte growth factor were assessed using immunochemical assays. Linear relationships were found between metabolic risk score and both plasma adiponectin (inverse, P = .02) and plasma leptin (P < .0001) at baseline after adjustment for several confounders. In overweight but not normal-weight children, plasma adiponectin at baseline was inversely associated with metabolic risk score 6 years later (P = .04). In childhood, both hypoadiponectinemia and hyperleptinemia accompany a negative metabolic risk profile. In addition, circulating plasma adiponectin may be a useful biomarker to identify overweight children at greater future risk of the cardiometabolic adverse effects of overweight.

AB - Prognostic biomarkers are needed to identify children at increased cardiometabolic risk. The objective was to study whether markers of metabolism and inflammation, for example, circulating plasma adiponectin, leptin, interleukin-8, and hepatocyte growth factor, are associated with cardiometabolic risk factors in childhood and adolescence. This was a cross-sectional and prospective study, and the setting was the Danish part of the European Youth Heart Studies I and II. Participants were randomly selected girls and boys 8 to 10 years of age with complete baseline data (n = 256) and complete follow-up data 6 years later (n = 169). Cardiometabolic risk profile was calculated using a continuous composite score derived from summing of 6 factors standardized to the sample means (Z scores): body mass index, homeostasis model assessment of insulin resistance, total serum cholesterol to serum high-density lipoprotein cholesterol ratio, serum triglycerides, systolic blood pressure, and the reciprocal value of fitness (maximum watts per kilogram). Overweight was defined using international classification of body mass index cutoff points for children. Plasma adiponectin, leptin, interleukin-8, and hepatocyte growth factor were assessed using immunochemical assays. Linear relationships were found between metabolic risk score and both plasma adiponectin (inverse, P = .02) and plasma leptin (P < .0001) at baseline after adjustment for several confounders. In overweight but not normal-weight children, plasma adiponectin at baseline was inversely associated with metabolic risk score 6 years later (P = .04). In childhood, both hypoadiponectinemia and hyperleptinemia accompany a negative metabolic risk profile. In addition, circulating plasma adiponectin may be a useful biomarker to identify overweight children at greater future risk of the cardiometabolic adverse effects of overweight.

U2 - 10.1016/j.metabol.2009.06.014

DO - 10.1016/j.metabol.2009.06.014

M3 - Journal article

C2 - 19716142

VL - 58

SP - 1817

EP - 1824

JO - Metabolism

JF - Metabolism

SN - 0026-0495

IS - 12

ER -